Drug Profile
Research programme: bacteriophage therapeutics - Fraunhofer ITEM/Leibniz Institute DSMZ German Collection of Microorganisms and Cell Cultures/Charite Universitatsmedizin Berlin
Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Charite - Universitatsmedizin Berlin; Fraunhofer-Institute for Toxicology and Experimental Medicine; Leibniz-Institut DSMZ - German Collection of Microorganisms and Cell Cultures
- Developer Charite - Universitatsmedizin Berlin
- Class Antibacterials
- Mechanism of Action Bacterial DNA modulators; Bacterial RNA modulators; Cell membrane modulators; Cell wall modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for research development in Bacterial-infections in Germany (Parenteral)
- 09 Nov 2017 Fraunhofer Institute for Toxicology and Experimental Medicine, Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, and Charite Universitatsmedizin Berlin collaborate for the development of bacteriophage therapeutics for Bacterial infections
- 09 Nov 2017 Early research in Bacterial infections in Germany (Parenteral)